Secondary prophylaxis with warfarin for recurrent thrombosis in a patient with Glanzmann thrombasthenia and F5 G1691A

British Journal of Haematology

Volumn 156, Issue 1, 2012, Pages 144-144

  Rezende, Suely Meireles ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

F5 G1691A (factor V Leiden); Glanzmann thrombasthenia; Thromboembolism; Thrombosis; Warfarin

Indexed keywords

ADENINE; GUANINE; WARFARIN;

ADULT; BLOOD EXAMINATION; CASE REPORT; DEEP VEIN THROMBOSIS; DIAGNOSTIC TEST; DISEASE ASSOCIATION; EPISTAXIS; F5 GENE; GENE; GENE MUTATION; GENETIC SCREENING; GINGIVA BLEEDING; GLANZMANN DISEASE; HETEROZYGOSITY; HUMAN; INTERNATIONAL NORMALIZED RATIO; LEG THROMBOSIS; LETTER; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; THROMBOCYTE AGGREGATION;

ADULT; ANTICOAGULANTS; FACTOR V; FAMILY HEALTH; FATAL OUTCOME; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; THROMBASTHENIA; THROMBOSIS; WARFARIN;

EID: 83555166022     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08821.x     Document Type: Letter

References (9)

1. Bertina, R.M., Koeleman, B.P.C., Koster, T., Rosendaal, FR, Dirven, RJ, de Ronde, H, van der Velden, PA & Reitsma, PH. (1994) Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature, 369, 64-67.
2. Coller, B.S. & Shattil, S.J. (2008) The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. Blood, 112, 3011-3025.
3. D'Andrea, G., Margaglione, M. & Glansmann's Thrombasthemia Italian Team (GLATIT). (2003) Glanzmann's thrombasthenia: modulation of clinical phenotype by alpha2C807T gene polymorphism. Haematologica, 88, 1378-1382.
4. Gruel, Y., Pacouret, G., Bellucci, S. & Caen, J. (1997) Severe proximal deep vein thrombosis in a Glanzmann thrombasthenia variant successfully treated with a low molecular weight heparin. Blood, 90, 888-890.
5. Imperiale, T.F. & Speroff, T. (1994) A meta-analysis of methods to prevent venous thromboembolism following total hip replacement. JAMA, 271, 1780-1785.
6. Jayanthi, A. & Liesner, R. (2010) Modern management of severe platelet function disorders. British Journal of Haematology, 149, 813-823.
7. Nichols, W.C., Amano, K., Cacheris, P.M., Figueiredo, M.S., Michaelides, K., Schwaab, R., Hoyer, L., Kaufman, R.J. & Ginsburg, D. (1996) Moderation of hemophilia A phenotype by the factor V R506Q mutation. Blood, 88, 1183-1187.
8. Pulmonary Embolism Prevention (PEP) Trial Collaborative Group (2000) Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet, 355, 1295-1302.
9. Ten Cate, H., Brandjes, D.P., Smits, P.H. & van Mourik, J.A. (2003) The role of platelets in venous thrombosis: a patient with Glanzmann's thrombasthenia and a factor V Leiden mutation suffering from deep venous thrombosis. Journal of Thrombosis and Haemostasis, 1, 394-395.